The Lancet. Oncology · 2024
Addressing challenges in low-income and middle-income countries through novel radiotherapy research opportunities.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Abdel-Wahab May, Coleman C Norman, Eriksen Jesper Grau, Lee Peter, Kraus Ryan, Harsdorf Ekaterina, Lee Becky, Dicker Adam, Hahn Ezra, Agarwal Jai Prakash, Prasanna Pataje G S, MacManus Michael, Keall Paul, Mayr Nina A, Jereczek-Fossa Barbara Alicja, Giammarile Francesco, Kim In Ah, Aggarwal Ajay, Lewison Grant, Lu Jiade J, Guedes de Castro Douglas, Kong Feng-Ming Spring, Afifi Haidy, Sharp Hamish, Vanderpuye Verna, Olasinde Tajudeen, Atrash Fadi, Goethals Luc, Corn Benjamin W
Аннотация
Although radiotherapy continues to evolve as a mainstay of the oncological armamentarium, research and innovation in radiotherapy in low-income and middle-income countries (LMICs) faces challenges. This third Series paper examines the current state of LMIC radiotherapy research and provides new data from a 2022 survey undertaken by the International Atomic Energy Agency and new data on funding. In the context of LMIC-related challenges and impediments, we explore several developments and advances-such as deep phenotyping, real-time targeting, and artificial intelligence-to flag specific opportunities with applicability and relevance for resource-constrained settings. Given the pressing nature of cancer in LMICs, we also highlight some best practices and address the broader need to develop the research workforce of the future. This Series paper thereby serves as a resource for radiation professionals.